J 2013

Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients

HALÁMKOVÁ, Jana, Igor KISS, Zdeněk PAVLOVSKÝ, Jiří TOMÁŠEK, Jiří JARKOVSKÝ et. al.

Basic information

Original name

Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients

Authors

HALÁMKOVÁ, Jana (203 Czech Republic, guarantor, belonging to the institution), Igor KISS (203 Czech Republic, belonging to the institution), Zdeněk PAVLOVSKÝ (203 Czech Republic, belonging to the institution), Jiří TOMÁŠEK (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Zbyněk ČECH (203 Czech Republic, belonging to the institution), D. BEDNAROVA (203 Czech Republic), Štěpán TUČEK (203 Czech Republic, belonging to the institution), L. HANAKOVA (203 Czech Republic), Mojmír MOULIS (203 Czech Republic, belonging to the institution), Jiřina ZAVŘELOVÁ (203 Czech Republic), M. MAN (203 Czech Republic), Petr BENDA (203 Czech Republic, belonging to the institution), Oldřich ROBEK (203 Czech Republic, belonging to the institution), Zdeněk KALA (203 Czech Republic, belonging to the institution) and Miroslav PENKA (203 Czech Republic, belonging to the institution)

Edition

Neoplasma, BRATISLAVA, SLOVAK ACAD SCIENCES, 2013, 0028-2685

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Slovakia

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.642

RIV identification code

RIV/00216224:14110/13:00071537

Organization unit

Faculty of Medicine

DOI

UT WoS

000320086800005

Keywords in English

plasminogen activator system; gastrointestinal cancer; plasminogen activator inhibitor 1; -675 4G/5G gene polymorphism

Tags

International impact, Reviewed
Změněno: 17/2/2014 16:11, Ing. Mgr. Věra Pospíšilíková

Abstract

V originále

Plasminogen activator ihnibitor (PAI 1) belongs to the plasminogen activator system, which is part of the metastatic cascade and significantly contributes to invasive growth and angiogenesis of malignant tumors. Its plasma level is normally low but 4G/4G homozygotes have higher concentrations of PAI 1. This genotype may be associated with worse prognosis and proximal location of colorectal cancer than 5G/5G homozygotes. In our prospective evaluation we examined plasma level PAI 1 (using photometric microplate method ELISA) pre-surgery and, subsequently, 6-8 weeks later, from 80 patients. For the PAI 1 rs1799889 -675 4G/5G polymorphism test the PCR amplification was used. Analysis of collected data was confirmed that significantly higher plasma levels of PAI 1 were found in patients before starting therapy, which decreased (p=0.004) after initiation of treatment. Patients with higher plasma level PAI 1 before (p=0.013) and after therapy (p=0.004) had significantly shorter survival. We found no relationship between polymorphisms of PAI 1 (-675 4G/5G) in relation to stage, survival or tumor location. PAI 1 is useful as a negative marker of prognosis and could be advantageous when planning adjuvant treatment of patients with colorectal carcinoma. Although opinions on the importance of polymorphisms of PAI 1 in relation to the prognosis are not uniform, it does seem that their role in the prognosis of patients with colorectal cancer is not essential.